Zanubrutinib – targeted therapy for various lymphoproliferative disorders

Abstract:

Bruton's tyrosine kinase inhibitors (BTKi) have brought a paradigm shift in the treatment of patients with B-cell lymphoproliferative disorders. The excellent efficiency and prolonged survival with BTKi gradually revealed the unwanted characteristics of individual BTKi in the terms of toxicity. Most of the side effects occurred due to the non-selective characteristics of BTKi, making it necessary to develop next-generation BTK inhibitors with greater selectivity. Zanubrutinib has satisfactory efficacy in its approved indications and appears to have reduced cardiovascular toxicity, particularly atrial fibrillation. Clinical research confirmed its effectiveness in B-cell lymphoproliferative disorders and brought a new choice in the first line of treatment, but also in relapsed/refractory disease.

Key words:
B-chronic lymphocytic leukemia; lymphoproliferative disorders; zanubrutinib; non-Hodgkin’s lymphoma